Diphtheritic neuropathy …

Yi Pan MD PhD

Peripheral Neuropathies

Updated 05.12.2026
Released 10.11.2004
Expires For CME 05.12.2029

Diphtheritic neuropathy

Author: Yi Pan MD PhD

See Contributor Disclosures

Editor: Louis H Weimer MD

Cite this article

Diphtheritic neuropathy

In This Article

Quick Link

Introduction

Overview

Diphtheritic neuropathy is an acute demyelinating polyneuropathy developing 3 to 5 weeks after severe diphtheria infection. It is a biphasic illness with initial bulbar and other cranial nerve involvement followed later by motor weakness in extremities and autonomic dysfunction. Symptoms are caused by an exotoxin, which inhibits protein synthesis and subsequent myelin production. There are a large number of differential diagnoses, the most important being Guillain-Barre syndrome. Diagnostic workup consists of confirming infection and neurophysiological evidence of demyelination. Management is conservative with attention paid to respiration and the airway, which may require mechanical ventilation if significantly impaired.

Key points

	• Diphtheritic neuropathy is an acute demyelinating polyneuropathy.
	• Latency in development of polyneuropathy varies from 2 to 6 weeks.
	• Typical presentation is early weakness in bulbar, followed by weakness in trunk, and later weakness in extremities.
	• Effective control includes universal immunization with diphtheria toxoid throughout life.

Historical note and terminology

Diphtheritic neuropathy is an acute demyelinating polyneuropathy, which has long been recognized as the most common severe complication of Corynebacterium diphtheriae infection. Diphtheria was recognized in 5th century BC by Hippocrates. The early history of diphtheritic neuropathy was reviewed by Rolleston a century ago (44). A definite relationship between diphtheria attack and subsequent paralysis was demonstrated during epidemics by Chomel in 1743, Ghisis in 1749, and Bard in 1789. The first monograph on diphtheritic paralysis was written by Maingault in 1854. Maingault was followed by other observers. The best known was Trousseau who collected 90 cases. He found paralysis of palate in 70 cases, generalized paralysis in 64 cases, and other symptoms including amaurosis, strabismus, sensory deficits, paralysis of lower limbs, truck, neck, rectum, and bladder (44). The first histological investigation was made by Meyer (32). The last diphtheritic epidemic was investigated in the former Soviet Union from 1990 to 1995 (39). Currently, diphtheritic neuropathy is a rare disease in Western Europe and the United States. However, diphtheria has reemerged globally after 2015 (33). Diphtheria cases, mainly cutaneous, were reported among migrants from Syria and Afghanistan arriving in Germany in 2022 (03), young migrant population in Belgium (28), asylum seekers in England (37), and Swiss (04). In the last 10 years, most diphtheritic neuropathy cases were reported from India (30; 29; 41; 15; 17), and they were reported most recently in Niger (27). In Pakistan, diphtheria has risen post-COVID-19 pandemic, causing more than 45 deaths in 2022 (45).

Clinical manifestations

Presentation and course

Diphtheritic neuropathy classically follows primary diphtheria infection, which usually involves tonsils, pharynx, and larynx with a characteristic membranous exudates, or skin. The severity of the diphtheritic polyneuropathy is also related to the severity of the diphtheria infection. Sixty percent of patients with diphtheritic polyneuropathy had a preceding severe diphtheria infection with cardiac and renal impairment (25). Young adults with diphtheria were reported with palatal paralysis in 15% and polyneuropathy in 11% of cases observed during the Second World War (38). A 15% incidence of neurologic complications was reported in adults from age 41 years to 60 years (25). In children, the incidence of diphtheritic polyneuropathy was reported 20% to 27% at the turn of the century (44). Recent pediatric cases of diphtheritic polyneuropathy were reported: palatal palsy in 44% to 64%, and limb muscle weakness in 22% to 94% (20; 29; 41; 15; 17).

Piradov and colleagues reported that the latency in development of diphtheritic polyneuropathy varies from 18 to 46 days after the initial infection (39). In children, diphtheritic polyneuropathy occurred 5 to 36 days after the onset of diphtheria infection (15; 17). Neurologic manifestations of diphtheria are biphasic, characteristically producing early bulbar disturbance and late motor weakness in the truck and extremities. Improvement in cranial nerves occurs with evolving motor disturbance in the trunk and extremities. Krumina and colleagues found that patients vaccinated against diphtheria developed mild limb polyneuropathy of later onset, with a median onset of 43 days (range 35 to 58), and less prominent early bulbar features (23).

The disturbance of cranial nerves IX, X (100%), VII (88%), III, IV, VI, XI (84%), XII (72%), and V (53%) were most frequently observed during weeks 3 through 5 of initial diphtheria in Piradov’s group (39). The symptoms are numbness in gingivae, tongue, and face, nasal speech, nasal regurgitation, difficulty in reading, diplopia, dysphonia, and dysphagia. Physical examination reveals accommodation, convergence or papillary light reflex disturbance, anisocoria, ptosis, mydriasis, palate paralysis, laryngeal paralysis or spasm, and weakness sternocleidomastoid muscles and tongue (24).

Generalized peripheral neuropathy usually appears in 5 to 8 weeks. Maximal weakness was reported on day 51+10 days in Piradov’s group (39). Weakness is usually in proximal or distal limbs followed by atrophy in severe cases. Hypotonia and gait abnormality are also found. Paralysis of the diaphragm and respiratory muscles were observed, requiring mechanical ventilation from 17 to 62 days. Patients have sensory disturbances in all modalities with numbness, paresthesia of distal extremities, and sensory ataxia. Tendon reflexes are depressed or absent. Plantar responses are typically flexor (46; 47; 43).

Autonomic disturbance is present in diphtheritic polyneuropathy, with the incidence ranging from 36% to 100% in severe diphtheritic polyneuropathy as reported from different authors. Autonomic neuropathy produces prominent abnormalities of parasympathetic reflexes and normal sympathetic function (16). Patients may have sinus tachycardia, arterial hypotension, urinary retention, hyperkeratosis and xeroderma, or hyperhidrosis of the face, neck, and chest. It may be difficult to differentiate myocarditis from autonomic instability.

In a review of 50 cases of diphtheritic polyneuropathy, the peak severity was a median of 49 (range 15 to 83 days) days after onset diphtheria and improvement started 73 (range 20 to 115 days) days in Logina and Donaghy’s group (25).

Prognosis and complications

The overall fatality rate of diphtheria was 2.4% in the 1940s and remained 2% to 3% in the outbreak in Russia (42). Mortality increases with severity of local disease and delay in administration of antitoxin. Roche and colleagues reported that antibiotic therapy in combination with antitoxin administration within 48 hours decreases the subsequent development of diphtheritic polyneuropathy by 50% (43). Piradov and colleagues reported an inverse relationship between diphtheritic polyneuropathy latency and neurologic recovery (39). A longer latency was associated with early regression. Systemic organ failure is the most influential factor on survival in diphtheritic polyneuropathy, as death due to bulbar or respiratory failure is preventable by endotracheal intubation and mechanical ventilation. Diphtheritic myocarditis is the major cause of death, and pneumonia occurs in more than half of fatal cases (05). Although pediatric cases presented with severe symptoms, the prognosis was good with duration of recovery 1 to 7 weeks in isolated bulbar palsy, and 6 to 17 weeks with limb paresis (41; 15; 17). In a follow up of 50 patients with diphtheritic polyneuropathy, Logina and Donaghy found the average duration of hospitalization to be 34.4 (range 7 to 101 days) days (25). Of this group, eight patients (16%) died, with four deaths due to cardiac arrhythmias, and four deaths from severe septic complications. Follow-up at one year in 34 of these patients found 14 (41%) unable to return to manual work but able to walk, whereas two (6%) required walking aid, and 80% still continued to have limb paresthesia, numbness, and weakness. In Piradov’s group, there was a complete recovery in 30 out of 32 patients. Two patients died because of pneumonia and acute cardiovascular insufficiency (39).

Biological basis

Etiology and pathogenesis

Diphtheria neuropathy is an acute toxin-mediated disease caused by Corynebacterium diphtheriae. C diphtheriae is an aerobic gram-positive bacillus. Three biotypes (mitis, intermedius and gravis) are capable of causing diphtheria. They are differentiated by colonial morphology and hemolysis as well as fermentation reactions (18). C diphtheriae exclusively resides in the mucous membrane and skin of humans. Diphtheria spreads via airborne respiratory droplets or direct contact with respiratory secretions of symptomatic individuals or infected skin lesions. Asymptomatic carriers are also important in transmission.

Diphtheritic neuropathy is characterized by paranodal demyelination, and segmental demyelination at ventral and dorsal spinal roots or peripheral nerves. Axonal continuity is usually preserved, but occasionally there might be complete degeneration resulting in destruction of axon and myelin (11; 26; 30; 41). C diphtheriae produces a 62-kd polypeptide exotoxin, which inhibits protein synthesis and causes local tissue necrosis. The toxin is comprised of two subunits. Fragment-B facilitates the entry of fragment-A into cells. Fragment-A catalyzes the transfer of an adenosine diphosphoribose component of the nicotinamide adenine dinucleotide molecule to elongation factor-2 and thereby inhibits protein synthesis. The covalent linking of factor-2 to adenosine diphosphoribose renders it nonfunctional and leads to subsequent disruption of protein synthesis, causing cell necrosis (19). Pleasure and colleagues found that diphtheria toxin does not increase the degradation of myelin lipid or proteins, but the toxin inhibits the synthesis of myelin proteolipid and other basic proteins, leading to a demyelinating neuropathy (40). Toxin absorption also causes local tissue necrosis, kidney tubules necrosis, thrombocytopenia, and cardiomyopathy. The biphasic clinical presentation may be explained by early bulbar disturbance through direct toxin spread and late motor disturbance in the trunk and extremities from hematogenous dissemination (31).

Epidemiology

Diphtheria was a dreaded, highly endemic childhood disease found in temperate climates. In the early twentieth century, it was one of the leading causes of death in children. The introduction of routine immunization with diphtheria toxoids in the 1940s and 1950s led to a dramatic reduction in the industrialized world. In the Unites States, the number of cases has decreased from 60,000 cases in 1932 to five cases in 1982. There were seven outbreaks of diphtheria from 1971 to 1981 in the United States, with high attack rates for American Indians. After 1979, cutaneous diphtheria was no longer tracked. Only 24 cases of diphtheria have been reported from 1980 to 1989 (02). Since the mid-1980s, there has been striking resurgence of diphtheria in several countries in Eastern Europe. In 1993, the World Health Organization received 15,211 diphtheria cases in Russia and 2,987 cases in Ukraine. The main reason for this return was decreased immunization coverage among infants and children, waning immunity in adults, population migration, and irregular vaccine supply (13). Since 1994, aggressive immunization efforts have led to a decrease in reported cases. In India between January 2009 to January 2011, 200 diphtheria cases were reported, and of this number, 150 patients had inadequate immunization (22). The World Health Organization reported a total of 8819 cases of diphtheria worldwide in 2017, the most since 2004. In countries with higher case counts, 66% of case patients were unvaccinated and 63% were younger than 15 years of age (06). There were 5125 diphtheria cases in 2000 and 4233 in 2011 in India (15). In February 2023, 216 confirmed diphtheria cases were found by the Nigeria Centre for Disease Control (01). There is no racial or sexual predilection. Diphtheria has shifted from an endemic affliction of children to a disease of adults due to a lack of natural exposure to toxigenic C diphtheria in the vaccination era or low rates of booster injections. In serosurveys in the United States, Sweden, Italy, and Denmark, 25% to 60% of adults lacked protective antitoxin, especially among the elderly (12). In a report from Sao Paulo, Brazil, 84% of 374 individuals had full protection from diphtheria, 15% had basic protection, and 1% was susceptible to the disease (08). Serum IgG anti-diphtheria antibody levels can assist in estimating the susceptible population. Seroprotection was 55.63% between 1986 to 2005, 67.11% between 2006 to 2015, and dropped to 45.75% between 2016 to 2023. Geographically, Western Pacific region and African regions had lower seroprotectivity (33).

Prevention

The only measure for effective control against diphtheria is universal immunization with diphtheria toxoid throughout life. This provides constant protective antitoxin levels. Immunization decreases local spreading, decreases the transmission of the organism, and prevents the carriage of toxigenic C diphtheria. The conventionally accepted minimum protective level of serum antitoxin is 0.01 IU/mL with 0.1 IU/mL, providing definite protective level (35). Diphtheria and tetanus toxoid with pertussis are the vaccine of choice for children 6 weeks through 6 years. The usual schedule is a primary series of four doses at 2 months, 4 months, 6 months, and 15 to 16 months of age as CDC recommended. If pertussis vaccine is contraindicated, then pediatric diphtheria and tetanus toxoid should be used to complete vaccination. The level of coverage for routine vaccination in low-income and middle-income countries was still under 80% in 2009 (48). Worldwide in 2022, 14.3 million children were not vaccinated with DTPcv1, most (84%) in low- and lower-middle-income countries (21). Antitoxin levels wane over time. Most individuals have antitoxin levels below optimum levels 10 years after the first dose. In 128 healthy individuals who had been administered at least one dose of the vaccine, 49.2% exhibited only minimal protection against diphtheria, which emphasized the need for periodical booster immunization (10). Tetanus toxoid should be given with diphtheria toxoid every 10 years. Diphtheria disease does not confer immunity and individuals recovering from diphtheria should begin or complete active immunization during convalescence.

Roche and colleagues reported that antibiotic therapy in combination with antitoxin administration within 48 hours decreases the subsequent development of diphtheritic polyneuropathy by 50% (43). The incidence of diphtheritic polyneuropathy seems to be reduced if antitoxin is administered during the first 2 days of diphtheritic infection. Antitoxin administered after day 2 does not modify the severity of neuropathy. Diphtheria antitoxin was used in 709 diphtheritic patients of Rohingya refugees in Bangladesh from 2017 to 2018 (09). Out of the patients, 98% of patients recovered from diphtheria, and about 25% of patients had at least one adverse reaction. Common reactions included cough (16%), rash (9%), and itching (5%). Three percent had severe hypersensitivity reactions (09).

Diagnostic workup

Diagnostic workup to confirm infection combines isolation of C diphtheria on culture with toxigenic testing. Nasopharyngeal swab is obtained from the patient and the contacts. Isolation from close contacts may confirm the diagnosis, even if the culture on specimen from the patient is negative. C diphtheria requires special culture median containing tellurite. Elek test is performed to determine if the bacillus produces toxin. As toxigenic testing is not readily available, state health department or CDC may provide information. Measurement of serum antibodies to diphtheria toxin may also help assess the probability of diphtheria. PCR can confirm infection with toxigenic strain but is not commercially available. Clinical samples should be sent to the CDC diphtheria laboratory for testing.

A variety of changes in the CSF in diphtheritic polyneuropathy have been described. Both lymphocytosis and dissociated increase of protein have been recorded. However, there was no parallel between anomalies of CSF and seriousness of clinical signs. In 27 cases with severe diphtheritic polyneuropathy, Piradov and colleagues found increase of CSF pressure from 200 to 440 mm H2O in nine cases (39). The CSF protein was 15 to 283 mg/dl, and the cell count (lymphocytes and neutrophils) was never more than 12 mm3.

Diphtheritic polyneuropathy is characterized by demyelination. Nerve conduction studies show prolongation of distal motor latency, delayed F-wave latency, slowing of conduction velocity, and if severe, conduction block and temporal dispersion (07). There is, however, a dissociation of clinical and electrical findings. The conduction abnormalities are mild, even when limb weakness is marked in the first few weeks (14). The delay in development of conduction abnormality is probably because changes in the peripheral segments of nerves appear later than in the ganglia and roots. Axonal degeneration, possibly secondary to demyelination, was reported in six of nine patients in a recent study (Prasad & Rai 2018). Autonomic tests showed impairment of R-R variation and Valsalva testing. Brainstem auditory evoked potentials may identify auditory nerve impairment (36).

The biopsies of nerves show paranodal and segmental demyelination with preservation of axonal continuity, or axonal degeneration secondary to demyelination in severe cases, and thin myelin sheaths with short internodes (34). Lozhnikova and colleagues found remyelination began after 35 days from onset diphtheria (26). Muscle biopsy showed neurogenic atrophy with no inflammation (47; 07).

References

01: Adegboye OA, Alele FO, Anton Pak A, et al. A resurgence and re-emergence of diphtheria in Nigeria, 2023. Ther Adv Infect Dis 2023;28;10:20499361231161936. PMID 37008790
02: Anonymous. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991;40(RR-10):1-28.
03: Badenschier F, Berger A, Dangel A, et al. Outbreak of imported diphtheria with Corynebacterium diphtheriae among migrants arriving in Germany, 2022. Euro Surveill 2022;27(46):2200849. PMID 36398576
04: Brockhaus L, Urwyler P, Leutwyler U, et al. Diphtheria in a Swiss asylum seeker reception centre: outbreak investigation and evaluation of testing and vaccination strategies. Int J Public Health 2024:69:1606791. PMID 38721474
05: Burkhardt E, Eggleston C, Smith LW. Electrocardiographic changes and peripheral nerve palsies in toxic diphtheria. Am J Med Sci 1938;195:301-13.
06: Clarke K, MacNeil A, Hadler S, Scott C, Tiwari T, Cherian T. Global epidemiology of diphtheria, 2000-2017. Emerg Infect Dis 2019;25(10):1834-42. PMID 31538559
07: Creange A, Meyrignac C, Roualdes B, Degos J, Gherardi RK. Diphtheritic neuropathy. Muscle Nerve 1995;18(12):1460-3. PMID 7477070
08: Divino-Goes KG, Moraes-Pinto MI, Dinelli MI, et al. Prevalence of diphtheria and tetanus antibodies and circulation of Corynebacterium diphtheriae in São Paulo, Brazil. Braz J Med Biol Res 2007;40(12):1681-7. PMID 17906776
09: Eisenberg N, Panunzi I, Anja Wolz A, et al. Diphtheria antitoxin administration, outcomes, and safety: response to a diphtheria outbreak in Cox's Bazar, Bangladesh. Clin Infect Dis 2021;202;73(7):e1713-18. PMID 33245364
10: Faryal R, Noreen Z, Tahir F, Rehman Z. Report: seroprevalence of corynebacterium diphtheriae among vaccinated population of Rawalpindi/Islamabad, Pakistan. Pak J Pharm Sci 2013;26(3):649-51. PMID 23625444
11: Fisher CM, Adams RD. Diphtheritic polyneuritis: a pathological study. J Neuropathol Exp Neurol 1956;15(3):243-68. PMID 13346392
12: Galazka AM, Robertson SE. Diphtheria: changing patterns in the developing world and the industrialized world. Eur J Epidemiol 1995;11(1):107-17. PMID 7489768
13: Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol 1995;11(1):95-105. PMID 7489783
14: Ghanem Q. Serial measurements of nerve conduction velocity and F-wave latency in diphtheritic neuropathy. Muscle Nerve 1993;16(9):985-6. PMID 8355737
15: Gowda VK, Vignesh S, Benakappa A, Benakappa N, Shivappa SK. Clinical profile and outcome in children with post diphtheritic paralysis in a tertiary care hospital in Southern India. Iran J Child Neurol 2022;16(2):107-15. PMID 35497109
16: Idiaquez J. Autonomic dysfunction in diphtheritic neuropathy. J Neurol Neurosurg Psychiatry 1992;55(2):159-61. PMID 1311373
17: Jammar SK, Sharma S, Agarwal S, et al. Spectrum of neurological outcomes in diphtheria: a case series. Indian J Otolaryngol Head Neck Surg 2022;74(Suppl 3):5454-9. PMID 36742785
18: Jill EC. Gram positive bacilli. In: Howard BJ, Klaes J II, Rubin SJ, Tilton RC, editors. Clinical and pathogenic microbiology. St. Louis, MO: Mosby Company, 1987:417-33.
19: Jolly RD. The pathogenic action of the exotoxin of Corynebacterium ovis. J Comp Pathol 1965;75(4):417-31. PMID 5892908
20: Kanwal SK, Yadav D, Chhapola V, Kumar V. Post-diphtheritic neuropathy: a clinical study in paediatric intensive care unit of a developing country. Trop Doct 2012;42(4):195-7. PMID 23146909
21: Kaur G, Danovaro-Holliday MC, Mwinnyaa G, et al. Routine vaccination coverage - worldwide, 2022. MMWR Morb Mortal Wkly Rep 2023;72(43):1155-61. PMID 37883326
22: Kole AK, Roy R, Kar SS, Chanda D. Outcomes of respiratory diphtheria in a tertiary referral infectious disease hospital. Indian J Med Sci 2010;64(8):373-7. PMID 22945781
23: Krumina A, Logina I, Donaghy M, et al. Diphtheria with polyneuropathy in a closed community despite receiving recent booster vaccination. J Neurol Neurosurg Psychiatry 2005;76(11):1555-7. PMID 16227550
24: Kurdi A, Abdul-Kader M. Clinical and electrophysiological studies of diphtheritic neuritis in Jordan. J Neurol Sci 1979;42(2):243-50. PMID 479913
25: Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1999;67(4):433-8. PMID 10486387
26: Lozhnikova SM, Sakharova AV, Pirogov VN, Piradov MA. Diphtheritic polyneuropathy: clinical and ultrastructural studies. Eur J Neurol 1997;4(Suppl 1):S102.
27: Mahamadou D, Abdoul-Aziz AB, Moustapha LM et al. The resurgence of diphtheria in Zinder, Niger. Infect Dis Now 2024;54(8):104979. PMID 39313157
28: Mangion JP, Mancini S, Bachy C, Weggheleire A, F Zamatto AF. Diphtheria in Europe. Public Health Action 2023;13(2):31-33. PMID 37359068
29: Manikyamba D, Satyavani A, Deepa P. Diphtheritic polyneuropathy in the wake of resurgence of diphtheria. J Pediatr Neurosci 2015;10(4):331-4. PMID 26962337
30: Mateen FJ, Bahl S, Khera A, Sutter RW. Detection of diphtheritic polyneuropathy by acute flaccid paralysis surveillance, India. Emerg Infect Dis 2013;19(9):1368-73. PMID 23965520
31: McAuley JH, Fearnley J, Laurence A, Ball JA. Diphtheritic polyneuropathy. J Neurol Neurosurg Psychiatry 1999;67(6):825-6. PMID 10567512
32: Meyer P. Anatomische untersuchungen uber diphtheritische lahmung. Virchows Arch Pathol Anat Physiol 1881;85:181.
33: Mital AK, Choudhary P, Padhi BK, et al. Mapping anti-diphtheria toxin antibody: a systematic review and meta-analysis with multi-level meta-regression. Pathog Glob Health 2025;119(1-2):48-59. PMID 39651759
34: Morgan-Hughes JA. Experimental diphtheritic neuropathy. A pathological and electrophysiological study. J Neurol Sci 1968;7(1):157-75. PMID 4301361
35: Mortimer EA Jr, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia, PA: W.B. Saunders Company, 1999:140-57.
36: Nikitin SS, Suopneva NA, Fedin PA, et al. The analysis of brainstem acoustic evoked potentials in diphtheritic polyneuropathy. Zh Nevrol Psikhiatr Im S S Korsakova 2005;105(11):35-8. PMID 16329633
37: O'Boyle S, Barton HE, D'Aeth JC, et al. National public health response to an outbreak of toxigenic Corynebacterium diphtheriae among asylum seekers in England, 2022: a descriptive epidemiological study. Lancet Public Health 2023;8(10):e766-75. PMID 37777286
38: Palley RG, Truelove SC. Diphtheria in the army in the United Kingdom. A study of its complications. J Royal Army Med Corps 1948;90:109-16.
39: Piradov MA, Pirogov VN, Popova LM, Avdunina IA. Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol 2001;58(9):1438-42. PMID 11559316
40: Pleasure DE, Feldman B, Prockop DJ. Diphtheria toxin inhibits the synthesis of myelin proteolipid and basic proteins by peripheral nerve in vitro. J Neurochem 1973;20(1):81-90. PMID 4687209
41: Prasad PL , Rai PL. Prospective study of diphtheria for neurological complications. J Pediatr Neurosci. 2018;13(3):313-6. PMID 30271463
42: Rakhmanova AG, Lumio J, Groudstroem K, et al. Diphtheria outbreak in St. Petersburg: clinical characteristics of 1860 adult patients. Scand J Infect Dis 1996;28(1):37-40. PMID 9122631
43: Roche S, Stone S, Allen CM, Lange LS. Diphtheritic polyneuritis in an elderly woman: clinical and neurophysiological follow-up. Br J Clin Pract 1990;44(7):285-7. PMID 2169838
44: Rolleston JD. Clinical observations in diphtheria paralysis. Practitioner 1904;2:597-623.
45: Saeed M, Shahid MB, Naeem A, Tabassum S, Dave T. Diphtheria in Pakistan post-COVID-19, a potential public health threat: an update. Trop Med Health 2023;51(1):24. PMID 37165432
46: Scheid W. Diphtherial paralysis: an analysis of 2,292 cases of diphtheria in adults, which included 174 cases of polyneuritis. J Nerv Ment Dis 1952;116:1095-101. PMID 13045174
47: Solders G, Nennesmo I, Persson A. Diphtheritic neuropathy, an analysis based on muscle and nerve biopsy and repeated neurophysiological and autonomic function tests. J Neurol Neurosurg Psychiatry 1989;52(7):876-80. PMID 2549201
48: Tao W, Petzold M, Forsberg BC. Routine vaccination coverage in low- and middle-income countries: further arguments for accelerating support to child vaccination services. Glob Health Action 2013;6:20343. PMID 23639178

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Yi Pan MD PhD

Dr. Pan of VA St. Louis Health Care System has no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University received a consultant honorarium from Roche and Ovid Therapeutics.
See Profile

Former Authors

Ajitesh Rai MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: female=male
Heredity: none
Population groups selectively affected: none
Occupation groups selectively affected: none

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Diphtheritic neuropathy

Differential Diagnosis

Guillain-Barre syndrome
acute inflammatory demyelinating polyradiculoneuropathy
acute myelopathy
myasthenia gravis
acute botulism
- West Nile virus infection
- Lyme disease
- tick paralysis
- meningeal carcinomatosis
- paraneoplastic neuropathy
- vasculitic neuropathy
- heavy metal toxin
- acute porphyria
- polymyositis

Diphtheritic neuropathy …

Diphtheritic neuropathy

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Carbon disulfide neuropathy

Toxic peripheral neuropathies

Organophosphate neuropathy

Efgartigimod alfa and hyaluronidase-qvfc

Acrylamide neuropathy

Whipple disease

Neurolymphomatosis

Neuropathies associated with cryoglobulinemia

Diphtheritic neuropathy

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carbon disulfide neuropathy

Toxic peripheral neuropathies

Organophosphate neuropathy

Efgartigimod alfa and hyaluronidase-qvfc

Acrylamide neuropathy

Whipple disease

Neurolymphomatosis

Neuropathies associated with cryoglobulinemia

This is an article preview.
Start a Free Account
to access the full version.